Education
- Washington and Lee University School of Law, J.D., summa cum laude, 2014, managing editor, Washington and Lee Law Review
- Hamilton College, B.A., magna cum laude, 2009, philosophy and creative writing
Bar Admissions
- Pennsylvania
- New Jersey
Court Admissions
- U.S. Court of Appeals, Third Circuit (2015)
- U.S. District Court, Eastern District of Pennsylvania (2015)
- U.S. District Court, District of New Jersey
- Speaker, “Increasing Diversity in Clinical Trials: FDA Guidance and Industry Efforts,” Medmarc Webinar, October 26, 2022.
- Co-author, “A Model’s Credibility Is in the Details: FDA Draft Guidance on the Use of AI Models in Drug and Biological Product Development,” Troutman Pepper Locke, February 12, 2025.
- Podcast, “AI and Pharmacovigilance Under the FDA’s New Emerging Drug Safety Technology Program,” The Good Bot: Artificial Intelligence, Health Care, and the Law, December 11, 2024.
- Co-author, “Updated FDA Draft Guidance Instructs Sponsors on Content, Format, Timing, and Procedures for Submitting Diversity Action Plans for Clinical Studies,” Troutman Pepper, July 9, 2024.
- Podcast, “The FDA’s Response to AI Medical Innovation,” The Good Bot: Artificial Intelligence, Health Care, and the Law, June 25, 2024.
- Co-author, “FDA Issues Final Rule on Regulation of Laboratory Developed Tests,” Troutman Pepper, May 23, 2024.
- Co-author, “New FDA Guidance on AI and Medical Products,” Troutman Pepper, April 10, 2024.
- Co-author, “FDA Proposes New Rules for Prescription Drug Labeling,” Troutman Pepper, June 5, 2023.
- Co-author, “FDA Draft Guidance Instructs Sponsors on Content and Timing of Diversity Plans for Clinical Trials,” Troutman Pepper, June 14, 2022.
- Quoted, “FDA’s New Guidance Plan to Face Trump’s Transparency Efforts,” Bloomberg Law, December 27, 2024.